Ventyx Biosciences is shelving a drug after a mid-stage miss and failure.
The company was investigating VTX958, an allosteric TYK2 inhibitor, in patients with moderately …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.